Novavax to Participate in BofA Securities 2026 Health Care Conference
Rhea-AI Summary
Novavax (Nasdaq: NVAX) will participate in the BofA Securities 2026 Health Care Conference with a fireside chat on Wednesday, May 13, 2026 at 3:00–3:30 p.m. PT in Las Vegas. A webcast will be available on the company website and a replay will be accessible for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – NVAX
In the May 8 session, NVAX gained 9.53%, reflecting a notable positive market reaction. Argus tracked a peak move of +10.2% during that session. Our momentum scanner triggered 66 alerts that day, indicating high trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Q1 2026 earnings | Neutral | +15.6% | Reported Q1 2026 results with revenue decline but reiterated 2026 guidance. |
| Apr 29 | Earnings date notice | Neutral | -0.6% | Announced timing and access details for Q1 2026 earnings call. |
| Mar 30 | R&D leadership change | Positive | -4.3% | Appointed Dr. Robert Walker as EVP and Head of Research & Development. |
| Feb 26 | Investor conferences | Neutral | -9.4% | Planned participation in three March 2026 health care investor conferences. |
| Feb 26 | FY 2025 earnings | Positive | +17.4% | Reported Q4 and full‑year 2025 results with guidance and expense reduction targets. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-related announcements have recently coincided with notable positive moves, while leadership changes have seen at least one negative divergence.
Over recent months, Novavax has reported detailed quarterly and full-year results, with Q1 2026 revenue of $140M and reiterated 2026 guidance, and Q4/full‑year 2025 revenue of $147M and $1.123B respectively. These earnings events saw double‑digit positive price reactions. Other updates included multiple March 2026 investor conferences and the appointment of Dr. Robert Walker as EVP and Head of R&D, which drew a negative reaction. Today’s conference participation fits the pattern of ongoing investor outreach following major financial disclosures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Details: | ||||
Fireside Chat | ||||
Date: | Wednesday, May 13, 2026 | |||
Time: | 3:00 – 3:30 p.m. Pacific Time | |||
Location: | ||||
Conference | ||||
Event: | Investor Meetings | |||
Date: | Wednesday, May 13, 2026 | |||
A webcast of the fireside chat will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days.
About Novavax
Novavax, Inc. tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M® adjuvant and protein-based nanoparticles. The Company's corporate growth strategy is designed to deliver value via three key strategic pillars: partnering its technology, capital-efficient research and development (R&D) innovation and a lean and efficient operating model. This includes maximizing impact through partnerships for its marketed products (Nuvaxovid™, R21/Matrix-M™), Matrix technology and R&D assets. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Jim Kelly
844-668-2829
ir@novavax.com
Media
Yvonne Sprow
844-264-8571
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-bofa-securities-2026-health-care-conference-302765891.html
SOURCE Novavax, Inc.